This announcement is a separate document:
国泰君安证券股份有限公司关于上海证券交易所关于嘉必优生物技术（武汉）股份有限公司2022年业绩快报更正暨资产减值风险、补充确认关联交易等有关事项的问询函回复的核查意见
Guotai Junan Securities Co., Ltd.'s inspection opinion on the Shanghai Stock Exchange's response to the inquiry letter on matters relating to the correction of Jiabiyou Biotech (Wuhan) Co., Ltd.'s 2022 performance report, risk of asset impairment, addition
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.